ReShape Lifesciences Inc.

Equities

RSLS

US76090R2004

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.1698 ^USD	-4.61%		+2.72%	-32.00%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Apr. 01	Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024

ReShape Lifesciences Inc. Signs Exclusive License Agreement With Biorad Medisys for Obalon(R) Gastric Balloon System

September 21, 2023 at 08:31 am EDT

ReShape Lifesciences Inc. announced the signing of an exclusive, royalty-bearing license agreement with Biorad Medysis, Pvt. Ltd. (Biorad) to manufacture, commercialize and distribute the Obalon(R) Gastric Balloon System in India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and the Maldives. Based in Mumbai, India, Biorad is an established, science-driven medical device manufacturer that has successfully manufactured and sold innovative medical devices in the urology, gastroenterology, orthopedic and neurovascular industries, which is now expanding into the bariatric arena.

The license agreement provides $200,000 in upfront payments from Biorad to ReShape and ongoing license payments of 4% on gross sales of the Obalon Balloon System in the territories.

Latest news about ReShape Lifesciences Inc.

North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Certain Restricted Stock Units of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
Certain Warrants of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
Certain Options of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
Certain Common Stock of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System	Mar. 28	MT
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System	Mar. 28	CI
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex	Feb. 22	CI
Top Midday Gainers	Dec. 13	MT
North American Morning Briefing : Traders Await FOMC, Powell	Dec. 13	DJ
ReShape Lifesciences Gets FDA Approval for PMA Supplement Used in Latest Lap-Band	Dec. 12	DJ
ReShape Lifesciences®? Receives FDA PMA Supplement Approval for Its Next-Generation Lap-Band®? 2.0 FLEX	Dec. 12	CI
ReShape Lifesciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
ReShape Lifesciences Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2023	Nov. 09	CI
Transcript : ReShape Lifesciences Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q3 Revenue $2.2M, vs. Street Est of $2.4M	Nov. 08	MT
Sector Update: Health Care Stocks Lower Late Afternoon	23-09-29	MT
Sector Update: Health Care Stocks Declining Friday Afternoon	23-09-29	MT
ReShape Lifesciences Prices $3 Million Offering at $0.33 Per Unit	23-09-29	MT
ReShape Lifesciences Inc. Signs Exclusive License Agreement With Biorad Medisys for Obalon(R) Gastric Balloon System	23-09-21	CI
ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device	23-09-14	CI
Transcript : ReShape Lifesciences Inc., Q2 2023 Earnings Call, Aug 07, 2023	23-08-07
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q2 Revenue $2.3M, vs. Street Est of $2.6M	23-08-07	MT

Chart ReShape Lifesciences Inc.

Duration

Period

More charts

Company Profile

ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-19 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ReShape Lifesciences Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1698 USD

Average target price

1 USD

Spread / Average Target

+488.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
RESHAPE LIFESCIENCES INC.	-32.00%	3.98M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology